CYP3A activity and expression in nonalcoholic fatty liver disease

Drug Metabolism and Disposition

Volumn 43, Issue 10, 2015, Pages 1484-1490

  Woolsey, Sarah J ^a   Mansell, Sara E ^a   Kim, Richard B ^a   Tirona, Rommel G ^a   Beaton, Melanie D ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4BETA HYDROXYCHOLESTEROL; CHOLESTEROL; CYTOCHROME P450 3A; LUCIFERASE; MESSENGER RNA; MIDAZOLAM; UNCLASSIFIED DRUG; CYP3A PROTEIN, HUMAN;

4BETA HYDROXYCHOLESTEROL BLOOD LEVEL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYP3A4 GENE; DISEASE SEVERITY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER BIOPSY; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOLUNTEER; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84946197317     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065979     Document Type: Article

References (57)

1. Abdel-Razzak Z., Loyer P, Fautrel A., Gautier JC, Corcos L, Turlin B, Beaune P., and Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715.
2. Beaton MD, Chakrabarti S, Levstik M., Speechley M, Marotta P, and Adams P (2013) Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 37: 720-729.
3. Bedogni G, Miglioli L, Masutti F., Tiribelli C, Marchesini G, and Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44-52.
4. Bitter A, Rümmele P, Klein K., Kandel BA, Rieger JK, Nüssler AK, Zanger U.M., Trauner M., Schwab M, and Burk O (2014) Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Arch Toxicol DOI: 10.1007/s00204-014-1348-x [published ahead of print].
5. Bodin K, Bretillon L, Aden Y., Bertilsson L, Broomé U, Einarsson C, and Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 276:38685-38689.
6. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P., Horton JD, Cohen JC, Grundy SM, and Hobbs HH (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395.
7. Burk O and Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369:105-124.
8. Chalasani N, Gorski JC, Asghar M.S., Asghar A., Foresman B, Hall SD, and Crabb DW (2003) Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37:544-550.
9. Charlton MR, Burns JM, Pedersen R.A., Watt KD, Heimbach JK, and Dierkhising RA (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141:1249-1253.
10. DeGorter MK, Tirona RG, Schwarz U.I., Choi YH, Dresser GK, Suskin N, Myers K., Zou G, Iwuchukwu O, and Wei WQ, et al. (2013) Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 6:400-408.
11. Diczfalusy U, Nylén H, Elander P., and Bertilsson L (2011) 4b-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71:183-189.
12. Donato MT, Jiménez N, Serralta A., Mir J, Castell JV, and Gómez-Lechón MJ (2007) Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 21: 271-276.
13. Donato MT, Lahoz A, Jiménez N, Pérez G, Serralta A., Mir J, Castell JV, and Gómez-Lechón MJ (2006) Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 34:1556-1562.
14. Dostalek M, Court MH, Yan B, and Akhlaghi F (2011) Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 163:937-947.
15. Emery MG, Fisher JM, Chien J.Y., Kharasch ED, Dellinger EP, Kowdley KV, and Thummel KE (2003) CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38:428-435.
16. Fisher CD, Jackson JP, Lickteig A.J., Augustine LM, and Cherrington NJ (2008) Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82:959-964.
17. Fisher CD, Lickteig AJ, Augustine L.M., Ranger-Moore J, Jackson JP, Ferguson S.S., and Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
18. Gadd VL, Skoien R, Powell E.E., Fagan KJ, Winterford C, Horsfall L, Irvine K., and Clouston AD (2014) The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 59:1393-1405.
19. Ghoneim RH, Ngo Sock ET, Lavoie JM, and Piquette-Miller M (2015) Effect of a high-fat diet on the hepatic expression of nuclear receptors and their target genes: relevance to drug disposition. Br J Nutr 113:507-516.
20. Ghose R, Omoluabi O, Gandhi A., Shah P, Strohacker K, Carpenter K.C., McFarlin B., and Guo T (2011) Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 89:57-64.
21. Gong IY, Crown N, Suen C.M., Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter M.K., Woolsey S., and Tirona RG, et al. (2012) Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J 33: 2856-2864.
22. Gorski JC, Hall SD, Jones D.R., VandenBranden M., and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
23. Gorski JC, Vannaprasaht S, Hamman M.A., Ambrosius WT, Bruce MA, Haehner-Daniels B, and Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287.
24. Gu X, Ke S, Liu D., Sheng T, Thomas PE, Rabson A.B., Gallo MA, Xie W, and Tian Y (2006) Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 281: 17882-17889.
25. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
26. Halama B, Hohmann N, Burhenne J., Weiss J, Mikus G, and Haefeli WE (2013) A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 93:564-571.
27. Honda A, Miyazaki T, Ikegami T., Iwamoto J, Yamashita K, Numazawa M., and Matsuzaki Y (2010) Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS/MS. J Steroid Biochem Mol Biol 121:556-564.
28. Iwamoto J, Saito Y, Honda A., Miyazaki T, Ikegami T, and Matsuzaki Y (2013) Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease. Inflamm Bowel Dis 19:1278-1284.
29. Josephson F, Bertilsson L, Böttiger Y, Flamholc L., Gisslén M, Ormaasen V., Sönnerborg A, and Diczfalusy U (2008) CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol 64: 775-781.
30. Jover R, Bort R, Gómez-Lechón MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16:1799-1801.
31. Kolwankar D, Vuppalanchi R, Ethell B., Jones DR, Wrighton SA, Hall SD, and Chalasani N (2007) Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 5:388-393.
32. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, and Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
33. Leclercq I, Horsmans Y, Desager J.P., Delzenne N., and Geubel AP (1998) Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 28:410-416.
34. Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567.
35. Lin YS, Lockwood GF, Graham M.A., Brian WR, Loi CM, Dobrinska MR, Shen D.D., Watkins PB, Wilkinson GR, and Kharasch ED, et al. (2001) In-vivo phenotyping for CYP3A by a singlepoint determination of midazolam plasma concentration. Pharmacogenetics 11:781-791.
36. Loomba R and Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10:686-690.
37. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
38. Meyer zu Schwabedissen HE, Oswald S, Bresser C., Nassif A, Modess C, Desta Z., Ogburn ET, Marinova M, Lütjohann D, and Spielhagen C, et al. (2012) Compartment-specific gene regulation of the CAR inducer efavirenz in vivo. Clin Pharmacol Ther 92:103-111.
39. Michaut A, Moreau C, Robin M.A., and Fromenty B (2014) Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int 34:e171-e179.
40. Muntané-Relat J, Ourlin JC, Domergue J, and Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153.
41. Nelson DR, Zeldin DC, Hoffman S.M., Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
42. Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, and Pasanen M (2000) Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 33:893-901.
43. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre J.M., Maurel P., and Vilarem MJ (2000) Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274:707-713.
44. Schuetz E, Lan L, Yasuda K., Kim R, Kocarek TA, Schuetz J, and Strom S (2002) Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62:439-445.
45. Sivertsson L, Ek M, Darnell M., Edebert I, Ingelman-Sundberg M, and Neve EP (2010) CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells. Drug Metab Dispos 38:995-1002.
46. Sookoian S and Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53:1883-1894.
47. Spruiell K, Jones DZ, Cullen J.M., Awumey EM, Gonzalez FJ, and Gyamfi MA (2014) Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice. Biochem Pharmacol 89:399-412.
48. Stepanova M and Younossi ZM (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10:646-650.
49. Tirona RG, Lee W, Leake B.F., Lan LB, Cline CB, Lamba V, Parviz F., Duncan SA, Inoue Y, and Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
50. Tsunoda SM, Velez RL, von Moltke LL, and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
51. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161.
52. Wahlang B, Song M, Beier J.I., Cameron Falkner K, Al-Eryani L, Clair H.B., Prough RA, Osborne TS, Malarkey DE, and Christopher States J, et al. (2014) Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. Toxicol Appl Pharmacol 279:380-390.
53. Wang D, Guo Y, Wrighton S.A., Cooke GE, and Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11:274-286.
54. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
55. Yoshinari K, Takagi S, Yoshimasa T., Sugatani J, and Miwa M (2006) Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res 23:1188-1200.
56. Zain SM, Mohamed R, Mahadeva S., Cheah PL, Rampal S, Basu RC, and Mohamed Z (2012) A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in nonalcoholic fatty liver disease. Hum Genet 131:1145-1152.
57. Zhou C, Tabb MM, Nelson E.L., Grün F, Verma S., Sadatrafiei A, Lin M, Mallick S., Forman BM, and Thummel KE, et al. (2006) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280-2289.